Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.
Researchers want to see if bulumtatug fuvedotin works well against breast cancer. The people in this study have triple-negative breast cancer (TNBC) that came back or spread after treatment. 
The purpose of this study is to assess OBX-115 cellular therapy for people with advanced melanoma or lung cancer. The people in this study have melanoma or non-small cell lung cancer (NSCLC). Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery) and keep growing even after treatment.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
Researchers want to learn if the radiopharmaceutical therapy 177Lu-PSMA-617 is a safe treatment for people with glioma. Radiopharmaceutical therapy delivers radiation directly into a tumor to destroy cancer cells.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced mismatch repair-deficient rectal cancer. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery. 
In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.
This study is assessing the safety and effectiveness of giving tucatinib and trastuzumab followed by standard CAPOX chemotherapy (the drugs capecitabine and oxaliplatin) in people with locally advanced rectal cancer that has not yet been treated and makes a protein called HER2. Tucatinib and trastuzumab both block HER2, which stimulates cancer cell growth.
Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.   
The purpose of this study is to assess the safety and effectiveness of combining a "bivalent" vaccine with two agents that stimulate the immune system: a sugar called beta-glucan and a medication called GM-CSF. The treatment is designed to prevent the relapse of patients with high-risk neuroblastoma that is in complete remission. This bivalent vaccine works by stimulating an immune response against two different antigens, which are markers on the surface of a cell.
